Title : Inhibiting 6-phosphogluconate dehydrogenase reverses doxorubicin resistance in anaplastic thyroid cancer via inhibiting NADPH-dependent metabolic reprogramming.

Pub. Date : 2018 Apr 15

PMID : 29534964






13 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Inhibiting 6-phosphogluconate dehydrogenase reverses doxorubicin resistance in anaplastic thyroid cancer via inhibiting NADPH-dependent metabolic reprogramming. Doxorubicin phosphogluconate dehydrogenase Homo sapiens
2 Inhibiting 6-phosphogluconate dehydrogenase reverses doxorubicin resistance in anaplastic thyroid cancer via inhibiting NADPH-dependent metabolic reprogramming. NADP phosphogluconate dehydrogenase Homo sapiens
3 In our work, we identified that 6-phosphogluconate dehydrogenase (6PGD) is critically involved in the development of ATC resistance to doxorubicin. Doxorubicin phosphogluconate dehydrogenase Homo sapiens
4 In our work, we identified that 6-phosphogluconate dehydrogenase (6PGD) is critically involved in the development of ATC resistance to doxorubicin. Doxorubicin phosphogluconate dehydrogenase Homo sapiens
5 We found that 6PGD mRNA, protein and enzyme activity levels are significantly upregulated in ATC cells during the prolonged exposure to doxorubicin in a time-dependent manner. Doxorubicin phosphogluconate dehydrogenase Homo sapiens
6 6PGD inhibition by genetic and pharmacological approaches significantly inhibits growth and survival of ATC cells that are highly resistant to doxorubicin. Doxorubicin phosphogluconate dehydrogenase Homo sapiens
7 Consistently, 6PGD inhibition also sensitizes ATC cells to doxorubicin treatment. Doxorubicin phosphogluconate dehydrogenase Homo sapiens
8 Of note, we observed the decreased level of NADPH, NADH and enzymatic activity of sirtuin-1 in response to 6PGD inhibition in doxorubicin-resistant ATC cells. NADP phosphogluconate dehydrogenase Homo sapiens
9 Of note, we observed the decreased level of NADPH, NADH and enzymatic activity of sirtuin-1 in response to 6PGD inhibition in doxorubicin-resistant ATC cells. NAD phosphogluconate dehydrogenase Homo sapiens
10 Of note, we observed the decreased level of NADPH, NADH and enzymatic activity of sirtuin-1 in response to 6PGD inhibition in doxorubicin-resistant ATC cells. Doxorubicin phosphogluconate dehydrogenase Homo sapiens
11 Lactate level was also reduced by 6PGD inhibition. Lactic Acid phosphogluconate dehydrogenase Homo sapiens
12 All these indicate that 6PGD inhibition disrupts metabolic reprogramming in doxorubicin-resistant ATC cells. Doxorubicin phosphogluconate dehydrogenase Homo sapiens
13 Our work demonstrates 6PGD activation-mediated resistance in response to doxorubicin and provides an alternative therapeutic strategy to overcome resistance to chemotherapy for ATC treatment. Doxorubicin phosphogluconate dehydrogenase Homo sapiens